About: Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19
Creator	Reid, Tony Reid, Knox, Susan Oronsky, Arnold Oronsky, Bryan Ao-Ieong, Eilleen Cabrales, Knox, Oronsky, Tony, R Yalcin, Ozlem
Source	Elsevier; Medline; PMC
abstract	This article summarizes the likely attenuation properties of RRx-001 in COVID-19 based on its mechanism of action and the putative pathogenesis of the disease, which appears to activate inflammatory, oxidative and immune cascades with the potential to culminate in acute respiratory distress syndrome (ARDS), cytokine storm and death. An ongoing pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19 appears to present with three major patterns of clinical symptomatology: 1) mild upper respiratory tract infection, 2) non-life-threatening pneumonia and 3) severe pneumonia and ARDS that initially manifest as a mild prodrome lasting for 7-8 days before rapid clinical and radiological deterioration requiring ICU transfer. RRx-001 is a targeted nitric oxide (NO) donor. This small molecule, which has been evaluated in multiple Phase 1 – 2 clinical trials for cancer as well as a Phase 3 clinical trial for the treatment of small cell lung cancer called REPLATINUM (NCT03699956), is minimally toxic and demonstrates clear evidence of anti-tumor activity. During the course of these clinical trials it was noted that the rate of chronic obstructive pulmonary disease (COPD) exacerbation and pneumonia in actively smoking SCLC patients treated with RRx-001 is less than 1%. Due to extensive history of tobacco use, 40-70% of patients with lung cancer have COPD(1) and the expected rate of pulmonary infection in this population is 50-70%,(2) which was not observed in RRx-001 clinical trials. Moreover, in preclinical studies of pulmonary hypertension, RRx-001 was found to be comparable with or more effective than the FDA approved agent, Bosentan. The potential pulmonary protective effects of RRx-001 in patients with recurrent lung infections coupled with preclinical models demonstrating RRx-001-mediated reversal of pulmonary hypertension suggests therapeutic activity in patients with acute respiratory symptoms due to COVID 19. Clinical trials have been initiated to confirm the hypothesis that RRx-001 may be repurposed to treat SARS-CoV-2 infection.
has issue date	2020-07-07(xsd:dateTime)
bibo:doi	10.1053/j.seminoncol.2020.07.002
bibo:pmid	32718560
has license	no-cc
sha1sum (hex)	4715885a589d5f96e4f7c8be85feca46bac50b06
schema:url	https://doi.org/10.1053/j.seminoncol.2020.07.002
resource representing a document's title	Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19
has PubMed Central identifier	PMC7341953
has PubMed identifier	32718560
schema:publication	Semin Oncol
resource representing a document's body	covid:4715885a589d5f96e4f7c8be85feca46bac50b06#body_text
is schema:about of	named entity 'cascades' named entity 'Treatment' named entity 'Treatment' named entity 'MECHANISM OF ACTION' covid:arg/4715885a589d5f96e4f7c8be85feca46bac50b06 named entity 'disease' named entity 'cytokine storm' named entity '8 days' named entity 'COVID-19' named entity 'prodrome' named entity 'mechanism of action' named entity 'pathogenesis' named entity 'cytokine storm' named entity 'life-threatening' named entity 'SARS-CoV-2' named entity 'Desperate Measures' named entity 'antitumor' named entity 'infection' named entity 'pneumonia' named entity 'antitumor' named entity 'inflammatory state' named entity 'chemotherapy' named entity 'DLTs' named entity 'transcription factors' named entity 'traditional Chinese medicines' named entity 'azithromycin' named entity 'pneumonia' named entity 'ARDS' named entity 'IL-6' named entity 'nitric oxide' named entity 'cerebral malaria' named entity 'hypoxic' named entity 'NF-κB' named entity 'RBCs' named entity 'hypoxic tissues' named entity 'preclinical testing' named entity 'preclinical models' named entity 'IFN-α/β' named entity 'acute respiratory distress syndrome' named entity 'nitric oxide' named entity 'inflammatory mediator' named entity 'guanosine triphosphate' named entity 'preclinical models' named entity 'clinical trials' named entity 'lung edema' named entity 'acute respiratory distress syndrome' named entity 'PAH' named entity 'ventricular hypertrophy' named entity 'Oxidative stress' named entity 'NOS' named entity 'lung infections' named entity 'acute lung injury' named entity 'soluble guanylyl cyclase' named entity 'animal models' named entity 'bevacizumab' named entity 'nitric oxide' named entity 'upper respiratory infection' named entity 'acute respiratory distress syndrome' named entity 'bevacizumab' named entity 'antiviral' named entity 'preclinical models' named entity 'neutrophils' named entity 'cGMP' named entity 'ischemic' named entity 'morbidity' named entity 'endogenous' named entity 'Lancet Oncology' named entity 'Pulmonary arterial hypertension' named entity 'chemokines' named entity 'ventilator-induced lung injury' named entity 'sepsis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software